American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.
The SOLAR-1 and X2101 trials demonstrate long-term disease control can be attained for ≥18 months with alpelisib plus fulvestrant in patients with hard-to-treat HR-positive/HER2-negative advanced breast cancer. Read More ›

Many women with HR-positive breast cancer contend with emotional distress during prolonged adjuvant endocrine therapy. Behavioral interventions show promise as effective strategies to reduce stress and improve adherence to therapy. Read More ›

Breast cancer survivors may test positive for pathogenic germline variants 10 years after their original diagnosis. Germline genetic testing may be an important tool for managing care. Read More ›

Low socioeconomic status is associated with delayed access to age-appropriate cancer screenings due to cost of care. Read More ›

Perceived fatigability may be a more clinically relevant measurement of the effectiveness of exercise intervention on reducing fatigue among survivors of breast cancer. Read More ›

Advanced-stage diagnosis of breast cancer is associated with deprived-rural socioeconomic status in French women. Read More ›

Alpelisib may overcome resistance to CDK4/6 inhibitors in HR-positive/HER2-negative advanced breast cancer patients with shorter exposure to prior CDK4/6 inhibitor treatment. Read More ›

Lack of genetic counseling referrals in women diagnosed with breast cancer contribute to a gap between the need for and completion of genetic testing, reducing access to more personalized therapies for these patients. Read More ›

Alpelisib activity improves real-world progression-free survival in breast cancer patients with PIK3CA mutations when used in combination with fulvestrant compared with fulvestrant alone. Read More ›

Research indicates no significant improvement in breast cancer–specific survival in male breast cancer in the past 30 years. Read More ›

Page 4 of 29

Conference Correspondent Coverage is Brought to You by the Publishers of:
American Health & Drug Benefits
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications